Evidence map›Paper›PMID 32213035›Full record

ReviewUnited European gastroenterology journal2020

Clinical management of type C hepatic encephalopathy.

Lorenzo Ridola, Oliviero Riggio, Stefania Gioia, Jessica Faccioli, Silvia Nardelli

Open access · bronzeAbstract readCase ReportsReview
In one paragraph

Review in United European gastroenterology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Hepatic Encephalopathy: Diagnosis and Management.Journal of translational internal medicine · 2020
    Review
  9. Minimal hepatic encephalopathy and sleep disorders in patients with cirrhosis: Which comes first?Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Lorenzo RidolaDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Oliviero RiggioDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Stefania GioiaDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Jessica FaccioliDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Silvia NardelliDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type-C hepatic encephalopathy is a complex neurological syndrome, characteristic of patients with liver disease, causing a wide and complex spectrum of nonspecific neurological and psychiatric manifestations, ranging from a subclinical entity, minimal hepatic encephalopathy, to a deep form in which a complete alteration of consciousness can be observed: overt hepatic encephalopathy. Overt hepatic encephalopathy occurs in 30-40% of patients. According to the time course, hepatic encephalopathy is subdivided into episodic, recurrent and persistent. Diagnostic strategies range from simple clinical scales to more complex psychometric and neurophysiological tools. Therapeutic options may vary between episodic hepatic encephalopathy, in which it is important to define and treat the precipitating factor and hepatic encephalopathy and secondary prophylaxis, where the standard of care is non-absorbable disaccharides and rifaximin. Grey areas and future needs remain the therapeutic approach to minimal hepatic encephalopathy and issues in the design of therapeutic studies for hepatic encephalopathy.

Indexed as

Administration, OralAnti-Bacterial AgentsDrug Therapy, CombinationEndovascular ProceduresEnemaHepatic EncephalopathyHepatic VeinsHumansImaging, Three-DimensionalLactuloseLiver CirrhosisMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePortal VeinPrevalenceAnti-Bacterial AgentsLactuloseRifaximincirrhosisHepatic encephalopathyminimal hepatic encephalopathynon-absorbable disaccharidesrifaximinspontaneous portal-systemic shuntstransjugular intrahepatic portosystemic shunt

Identifiers

PMID32213035
PMCPMC7268947
OpenAlexW3008823225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.